Update PET/PET-CT evidence for need-based planning in Austria

02

Sep 2020

In July 2020, the Austrian Institute for Health Technology Assessment (AIHTA) issued an updated report on the PET/PET-CT evidence for need-based planning in Austria.

The report is an update of the two already published reports (2015 and 2018) of the Austrian Institute for Health Technology Assessment (AIHTA, formerly known as Ludwig Boltzmann Institute for HTA, LBI-HTA).

The present update aimed to identify oncological indications for which the use of PET/PET-CT is recommended or explicitly not recommended by relevant societies and in evidence-based guidelines.  The specific area of application (primary diagnosis, tumor grading, tumor staging/interim staging/re-staging, recurrence staging, and recurrence) for the respective oncological indication was additionally determined.

A comprehensive hand search in guideline databases, websites, and databases of national and supranational societies was performed. The search period was between 20.05.2020 and 19.06.2020. Also, a search for explicitly "inappropriate" recommendations against the application of PET/PET-CT was conducted. Generally, the selection of databases and websites was based on the LBI-HTA Report 2015 and the update from 2018. A total of 37 evidence-based guidelines were used.

The 2020 update resulted in a total of nine changes regarding the overall recommendations and one new cancer indication:

  • Esophageal carcinomas (limited, previously controversial)
  • Colorectal cancer (controversial, previously limited)
  • Ovarian cancer (limited, previously none)
  • Prostate cancer (controversial, previously none)
  • Testicular carcinoma (controversial, previously none)
  • Lymphomas (recommended, previously restricted)
  • Neuroendocrine carcinomas (recommended, previously controversial)
  • Pancreatic cancer (recommended, previously controversial)
  • Renal cancer (controversial, none before)
  • Endometrial cancer (new).

The overall recommendations of this update (as in previous years reports 2015 & 2018) rarely show any benefit from PET as a primary or standard diagnosis. This means that PET is usually part of a diagnostic chain or a treatment path based on previous undecided results, and should, therefore, only be used under specific obligations to prevent patient overtreatment/overuse. In general, the present summarized evidence of guidelines can support appropriate health care service provision in Austrian hospitals.

The full report in German can be found here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

23

Nov 2022

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 21738 of November 4, 2022, Tuscany Regional Healthcare has published assessments of three medical devices in the orthopedics, surgical procedures, and peripheral vascular areas.

Read more

11

Nov 2022

MedTech-related health technology assessments from NIHR in October 2022
In October 2022, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related report in its Health Technology Assessment (HTA) Journal, which concerned photodynamic versus white-light-guided resection of non-muscle-invasive bladder cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

09

Nov 2022

On October 31, 2022, the Dental and Pharmaceutical Benefits Agency (TLV) initiated conducting a theme survey for technologies used for the diagnosis or treatment of lung or colorectal cancer. Manufacturers of medical devices have an opportunity to notify TLV about a new product related to the theme of the survey. The notification form is available on the TLV website and should be submitted no later than November 22, 2022.

Read more

08

Nov 2022

In October 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (YAG laser vitreolysis for symptomatic vitreous floaters, transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine), one Medical Technologies Guidance (Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer) and three new Medtech Innovation Briefings (O2matic PRO 100, Daylight, Signatera). Also, one new clinical guideline was published on osteoarthritis.

Read more

31

Oct 2022

On October 12, 2022, the National Institute for Health and Care Excellence (NICE) announced the launch of an official collaboration with five other HTA bodies from Canada, Australia, Scotland, and Wales. The partners will remain independent and work together on shared priorities. Five initial priority areas have been agreed upon, including COVID-19, digital health, and Artificial Intelligence. The partnership could be expanded to include other HTA bodies in the future.

Read more